Are there any differences among non-steroidal anti-inflammatory drugs? Focus on nimesulide

Clinical Drug Investigation

Volumn 27, Issue SUPPL. 1, 2007, Pages 15-22

  Dallegri, Franco ^a   Ottonello, Luciano ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FLURBIPROFEN; HISTAMINE; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUMIRACOXIB; MATRIX METALLOPROTEINASE; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE; ROFECOXIB; SULINDAC; TUMOR NECROSIS FACTOR ALPHA; VALDECOXIB;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOTOXICITY; CARTILAGE CELL; CELL DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HISTAMINE RELEASE; HUMAN; KNEE OSTEOARTHRITIS; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATIC DISEASE; SKIN MANIFESTATION; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE AND BONES; CARTILAGE; HUMANS; INFLAMMATION MEDIATORS; SULFONAMIDES;

EID: 34247575272     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727001-00004     Document Type: Review

References (33)

1. Gotzsche PC. Musculoskeletal disorders. Non-steroidal anti-inflammatory drugs. Clin Evidence 2004; 12: 1702-10
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231: 232-5
3. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-8
4. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15
5. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 2006; 5: 75-86
6. Kean WF, Buchanan WW. The use of NSAIDs in rheumatic disorders 2005: a global perspective. Inflammopharmacology 2005; 13: 343-70
7. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8
8. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102
9. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91
10. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481-92
11. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80
12. Sciulli MG, Capone ML, Tacconelli S, et al. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. Pharmacol Rep 2005; 57 (Suppl): 66-85
13. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384: 644-8
14. Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48: 339-46
15. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 1991; 324: 1716-25
16. Bernareggi A. Clinical pharmacokinetics of nimesulide. Clin Pharmacokinet 1998; 35: 247-74
17. Herrera JA, Gonzalez M. Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis. Am J Ther 2003; 10: 468-72
18. Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000; 38: 225-42
19. Depre M, Ehrich E, Van Hecken A, et al. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000; 56: 167-74
20. Bennett A, Tavares IA. COX-2 inhibitors compared and contrasted. Expert Opin Pharmacother 2001; 2: 1859-76
21. 2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis. Drugs 2003; 63 (Suppl 1): 31-6
22. Bianchi M, Broggini M. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs 2003; 63 (Suppl 1): 37-46
23. Bianchi M, Ferrario P, Balzarini P, et al. Plasma and synovial fluid concentrations of nimesulide and its main metabolite after a single or repeated oral administration in patients with knee osteoarthritis. J Int Med Res 2006; 34: 348-54
24. Rainsford KD and Members of the Consensus Report Group on Nimesulide. Nimesulide - a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22: 1161-70.
25. Azab AN, Kaplanski J. A reduction of tumor necrosis factor-alpha in paw exudate of lipopolysaccharide treated rats by nimesulide. Life Sci 2001; 68: 1667-75
26. Ottonello L, Dapino P, Pastorino G, et al. Inhibition of the neutrophil oxidative response induced by the oral administration of nimesulide in normal volunteers. J Clin Lab Immunol 1992; 37: 91-6
27. Dallegri F, Ottonello L, Dapino P, et al. The anti-inflammatory drug nimesulide rescues alpha-1-proteinase inhibitor from oxidative inactivation by phagocytosing neutrophils. Respiration 1992; 59: 1-4
28. Rossoni G, Berti F, Buschi A, et al. New data concerning the antianaphylactic and antihistaminic activity of nimesulide. Drugs 1993; 46 (Suppl 1): 22-8
29. Saito S, Katoh M, Masumoto M, et al. Involvement of MMP-1 and MMP-3 in collagen degradation induced by IL-1 in rabbit cartilage explant culture. Life Sci 1998; 62: PL 359-65.
30. Wu JJ, Lark MW, Chun LE, et al. Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage. J Biol Chem 1991; 266: 5625-8
31. Kullich WC, Niksic F, Klein G. Effect of nimesulide on metalloproteinases and matrix degradation in osteoarthritis: a pilot clinical study. Int J Clin Pract Suppl 2002: 24-9.
32. Manicourt DH, Bevilacqua M, Righini V, et al. Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis. Drugs R D 2005; 6: 261-71
33. Mukherjee P, Rachita C, Aisen PS, et al. Non-steroidal antiinflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheumatol 2001; 19 (1 Suppl 22): S7-11